Abstract
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
Full text
PDF![713](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba97/185930/bc7a796ed0ca/aac00200-0109.png)
![714](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba97/185930/58a856c6cf72/aac00200-0110.png)
![715](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba97/185930/b53f91f5e0e2/aac00200-0111.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
- Phillpotts R. J. Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirus. J Virol Methods. 1983 May;6(5):267–269. doi: 10.1016/0166-0934(83)90041-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Phillpotts R. J., Scott G. M., Higgins P. G., Wallace J., Tyrrell D. A., Gauci C. L. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2. Antiviral Res. 1983 Aug;3(2):121–136. doi: 10.1016/0166-3542(83)90034-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Phillpotts R. J., Wallace J., Tyrrell D. A., Freestone D. S., Shepherd W. M. Failure of oral 4',6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol. 1983;75(1-2):115–121. doi: 10.1007/BF01314131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scott G. M., Phillpotts R. J., Wallace J., Gauci C. L., Greiner J., Tyrrell D. A. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982 Jul 24;2(8291):186–188. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
- Scott G. M., Phillpotts R. J., Wallace J., Secher D. S., Cantell K., Tyrrell D. A. Purified interferon as protection against rhinovirus infection. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1822–1825. doi: 10.1136/bmj.284.6332.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]